IPAB quashes revocation of Novartis patent for anti-cancer drug Ceritinib

[ad_1]


Natco filed a post-grant opposition against the patent on September 26, 2017, on grounds of obviousness and lack of inventive step.

[ad_2]

Source link

Leave a Comment

Your email address will not be published. Required fields are marked *

Polynion

Binance Prediction

Metamask

papamiaspizza.com

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99

RAJANAGA99